c-hep final book

THE 3RD WORLD CONGRESS ON

CONTROVERSIES IN THEMANAGEMENT OF VIRAL HEPATITIS

C-HEP

ISTANBUL, 2013See you there!

THE 2ND WORLD CONGRESS ON


C-HEP

BERLiN, GERmaNy • OCTOBER 18-20, 2012

PROGRAM

www.comtecmed.com/chep • [email protected]

C-HEP cover RUN.indd 1 4/10/12 15:18:51

You are cordially invited to attend the satellite symposium at the 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep)

DAAs: Raising Standards in Patient Care

Chair: Thomas Berg, Germany

on Thursday 18 October 2012, 18:00–19:15Hall A, Leonardo Royal Hotel Berlin, Germany

Janssen Pharmaceutica NV

With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA EMEA/HEP/0812/0804

C-HEP Advert A4_Layout 1 13/09/2012 10:25 Page 1

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBERLIN, GERMANY • OCTOBER 18-20, 2012

C-HEP PARTICIPANTS CAME FROM…

37 Countries (as of October 2, 2012)

Azerbaijan Bahrain Belgium Canada Czech Republic

Denmark Estonia Finland France Georgia

Germany Greece Hungary India Israel

Italy Japan Lithuania Luxembourg Malta

Nigeria Norway Poland Portugal Qatar

Romania Russia Serbia Slovak Republic Spain

Sweden Switzerland Thailand Turkey UK

USA Vietnam




C-HEP


PROGRAM









01-26-C-HEP-part 1.indd 3 4/10/12 15:07:43

01-26-C-HEP-part 1.indd 4 4/10/12 15:07:48

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBerlin, Germany • OctOBer 18-20, 2012

[ 5 ]

TIMETABLE

SATuRDAy, OCTObER 20, 2012HaLL a

08:30-10:30 PLENARy SESSION 10 HBV therapy in 2012

10:30-11:00 Coffee Break

11:00-11:45 PLENARy SESSION 11 interactive Case Session and Discussion: The challenging hepatitis B Case Supported by an unrestricted grant from Gilead Sciences Europe Ltd.

11:45-12:45 PLENARy SESSION 12 HCV – Looking to the Future

12:45-13:00 Farewell Toast

THuRSDAy, OCTObER 18, 2012HaLL a

14:00-16:00 PLENARy SESSION 1 Hepatitis C – addressing the Challenge

16:00-17:30 PIPELINE SHOWCASE New Drugs on the Horizon

17:30-18:00 Coffee Break and Poster Exhibition

18:00-19:15 SATELLITE SyMPOSIuM JANSSEN PHARMACEuTICALS Daas: Raising standards in patient care

19:15-20:30 Welcome Reception Sponsored by Abbott

FRIDAy, OCTObER 19, 2012HaLL a HaLL B

09:00-11:00 PLENARy SESSION 2 HCV Direct acting antivirals: How have the treatment paradigms changed


11:30-12:15 SESSION 3 SESSION 4 Do we need to know genetic factors such HCV therapy is for specialists only? as iL28B for treatment decision making?

12:15-13:00 Lunch

13:00-14:15 SATELLITE SyMPOSIuM MERCK SHARP & DOHME Successful HCV Treatment in the Real World: Lessons From Clinical Practice

14:15-15:45 PLENARy SESSION 5 Hepatitis: State of the art Clinical Care

15:45-16:15 Coffee Break and Poster Prize Ceremony

16:15-17:00 SESSION 6 SESSION 7 Should patients wait for Daa combination Resistance to HCV Protease inhibitors: therapy? Game over?

17:00-17:30 SESSION 8 SESSION 9 interactive Case Session: How to treat HCV interactive Case Session: How to treat HCV in relapse after Liver Transplant? HiV coinfection Supported by an unrestricted grant from Boehringer Ingelheim

01-26-C-HEP-part 1.indd 5 4/10/12 15:07:50

Value through Innovation

Boehringer Ingelheim Is Advancing

NEXT�GENERATION AGENTS

Aiming to Deliver Improved TreatmentsOur rigorous HCVersoTM clinical trial program is designed

to answer the difficult questions in HCV: how to reduce

the burden of treatment and cure more patients.

Ultimately, Eliminating the Need for InterferonWith interferon-free treatment regimens, we strive to reach our

goal of delivering a more convenient cure for patients.

The novel clinical investigational compounds may offer the

potential for new therapies with greater efficacy, improved

tolerability, and shorter treatment duration compared with

current approaches in HCV treatment.

If you would like to learn more about Boehringer Ingelheim, visit us at www.boehringer-ingelheim.com.

S:190 mmS:277 m

mT:210 mm

T:297 mm

B:216 mmB:303 m

m

01-26-C-HEP-part 1.indd 6 4/10/12 15:07:51


[ 7 ]

TABLE OF CONTENTS

Welcome Note 9

Committees 10

Faculty 12

CmE accreditation 15

Sponsors 16

acknowledgements 17

Exhibition Floorplan 21

Partners 22

Endorsements 23

General information 24

Scientific Program 27

Thursday, October 18, 2012 29

Friday, October 19, 2012 31

Saturday, October 20, 2012 34

index 35

Value through Innovation

Boehringer Ingelheim Is Advancing

NEXT�GENERATION AGENTS

Aiming to Deliver Improved TreatmentsOur rigorous HCVersoTM clinical trial program is designed

to answer the difficult questions in HCV: how to reduce

the burden of treatment and cure more patients.

Ultimately, Eliminating the Need for InterferonWith interferon-free treatment regimens, we strive to reach our

goal of delivering a more convenient cure for patients.

The novel clinical investigational compounds may offer the

potential for new therapies with greater efficacy, improved

tolerability, and shorter treatment duration compared with

current approaches in HCV treatment.

If you would like to learn more about Boehringer Ingelheim, visit us at www.boehringer-ingelheim.com.

S:190 mm

S:277 mm

T:210 mm

T:297 mm

B:216 mm

B:303 mm

01-26-C-HEP-part 1.indd 7 4/10/12 15:08:01


[ 8 ]

01-26-C-HEP-part 1.indd 8 4/10/12 15:08:09


[ 9 ]

DEAR FRIENDSAND COLLEAGUES,

Following the success of the 1st World Congress on Controversies in the management of Viral Hepatitis (C-Hep), we are very pleased to have you here in Berlin to participate in the 2nd C-Hep Congress.

The large attendance and enthusiastic feedback of the 1st Congress held last may in Barcelona highlighted the need for such a meeting focusing on the needs of the busy clinician caring for HCV and HBV infected patients. The C-Hep Congress attempts to summarize all the key new data recently presented – and how it might be implemented in routine care of Hepatitis B and C patients. Overviews, state of the art lectures and controversial debates with the outstanding faculty of prominent world leaders presenting both pro and con positions challenge and explore the optimal treatment for patients, including the appropriate use of new drugs. This educational Congress focuses on clinical practices in Viral Hepatitis and benefits not only Hepatologists and infectious Diseases specialist, but also general practitioners, internists and primary care physicians with a desire to gain knowledge in these exciting advances.

The format includes a significant allocation of time for interactive debates and questions from the audience to each panel of experts. Participants are encouraged to take an active role in the discussions with faculty members which follow each debate, in a unique and open environment.

We look forward to having you participate during the 2nd C-Hep Congress in the lovely city of Berlin.

Sincerely, Jürgen Rockstroh mD Jonathan M. Schapiro mD Germany israel

Co-Chairpersons

01-26-C-HEP-part 1.indd 9 4/10/12 15:08:14


[ 10 ]

Jürgen Rockstroh, mDGermany

Jonathan M. Schapiro, mDisrael

CO-ChAIRPERSONS

hCV PROGRAM DIRECTOR

Stefan Zeuzem, GermanyKlinikum der J.W. Goethe-Universitat, Med. Klinik 1

hBV PROGRAM DIRECTOR

Fabien Zoulim, FranceINSERM U1052, Lyon University, Hepatology Department, Hospices Civils de Lyon

01-26-C-HEP-part 1.indd 10 4/10/12 15:08:17


[ 11 ]

SCIENTIFIC COMMITTEE

David back, UKDepartment of Molecular and Clinical Pharmacology, University of Liverpool

Thomas berg, GermanyHead of the Division of Hepatology, Department of Internal Medicine, Clinic of Gastroenterology and Rheumatology, University Hospital Leipzig

Raffaele bruno, italyDepartment of Infectious Diseases, Hepatology Outpatients Unit, University of Pavia Fondazione IRCCS, Policlinico San Matteo, Pavia

Maria buti, SpainHospital Valle Hebron, Barcelona

bonaventura Clotet, SpainHIV Unit and irsicaixa Foundation, University Hospital “Germans Trias i Pujol”, Badalona, Catalonia

Douglas T. Dieterich, USa Professor of Medicine, Mount Sinai School of Medicine, New York

Geoffrey Dusheiko, UKUCL Centre for Hepatology, University College London Medical School, and Royal Free Hospital, London

Rafael Esteban, SpainVall d’Hebron University Hospital

Michael P. Manns, Germany Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology

Stefan Mauss, Germany Center for HIV and Hepatogastroenterology, Duesseldorf

Jean Michel Pawlotsky, France Department of Virology, Henri Mondor Hospital, University of Paris

Carlo Perno, italyTor Vergata University Hospital, Rome

Marion Peters, USa Chief of Hepatology Research, Division of Gastroenterology, University of California, San Francisco

Jörg Petersen, Germany Liver Unit, IFI Institute for Interdisciplinary Medicine, Asklepios Klinik St. Georg, Hamburg

Massimo Puoti, italyDepartment of Infectious Diseases. AO Ospedale Niguarda Ca’ Granda, Milan

Vicente Soriano, Spain Hospital Carlos III, Madrid

Mark R. Thursz, UK Professor of Hepatology, Imperial College, London

Hans L. Tillmann, USaDuke Clinical Research Institute

Heiner Wedemeyer, Germany Hannover Medical School

01-26-C-HEP-part 1.indd 11 4/10/12 15:08:26


[ 12 ]

FACULTY

Matthew Albert, FranceImmunobiology of Dendritic Cells, Institut Pasteur, Paris

David back, UKDepartment of Molecular and Clinical Pharmacology, University of Liverpool

Thomas berg, GermanyHead of the Division of Hepatology, Department of Internal Medicine, Clinic of Gastroenterology and Rheumatology, University Hospital Leipzig

Michel biermer, GermanyHepatologie und Gastroenterologie, University Hospital Leipzig

Raffaele bruno, italyDepartment of Infectious Diseases, Hepatology Outpatients Unit, University of Pavia Fondazione IRCCS, Policlinico San Matteo, Pavia

Maria buti, SpainHospital Valle Hebron, Barcelona

Geoffrey Dusheiko, UKUCL Centre for Hepatology, University College London Medical School, and Royal Free Hospital, London

Rafael Esteban, SpainVall d’Hebron University Hospital

Graham Foster, UKProfessor of Hepatology, Queen Marys University of London

Christoph Hezode, FranceHôpital Henri-Mondor, Université Paris-Est Créteil

Patrick Ingiliz, GermanyMedical Center for Infectious Diseases, Berlin

Karine Lacombe, FranceInfectious and Tropical Diseases Department, Saint-Antoine Hospital (AP-HP) & INSERM, UMR-S707 Paris

Christian M. Lange, Germany Department of Internal Medicine 1, Johann Wolfgang Goethe University Hospital Frankfurt a. M.

Maud Lemoine, FranceINSERM, UMR-S707 & Hopital Saint-Antoine, Paris

Michael P. Manns, Germany Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology

Stefan Mauss, Germany Center for HIV and Hepatogastroenterology, Duesseldorf

Marie-Louise Michel, France Pasteur Institut and Inserm U845, Paris

Mark Nelson, UKChelsea and Westminster Hospital, London

Claus Niederau, GermanyDirector of the Department of Medicine, Katholische Kliniken Oberhausen, St. Josef- and St. Marienhospital, Academic Teaching Hospital of the University of Duisburg-Essen

Jean Michel Pawlotsky, France Department of Virology, Henri Mondor Hospital, University of Paris

01-26-C-HEP-part 1.indd 12 4/10/12 15:08:39


[ 13 ]

FACULTY

Marion Peters, USaChief of Hepatology Research, Division of Gastroenterology, University of California, San Francisco

Jörg Petersen, Germany Liver Unit, IFI Institute, Asklepios Klinik St. Georg, Hamburg

Stanislas Pol, FranceStanislas Pol, France Université Paris Descartes & Hôpital Cochin, Paris

Massimo Puoti, italyDepartment of Infectious Diseases. AO Ospedale Niguarda Ca’ Granda, Milan

Jürgen Rockstroh, GermanyDepartment of Medicine, University Hospital Bonn

Christoph Sarrazin, GermanyProfessor of Medicine, Department of Internal Medicine 1, J.W. Goethe-University Hospital, Frankfurt

Jonathan M. Schapiro, israel National Hemophilia Center, Sheba Medical Center

Eckart Schott, GermanyDepartment of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin

Vicente Soriano, Spain Hospital Carlos III, Madrid

ulrich Spengler, GermanyProfessor for Hepatotology, Department of Medicine, University Hospital Bonn

Mark R. Thursz, UK Professor of Hepatology, Imperial College, London

Florian van bömmel, GermanyDepartment of Hepatology and Gastroenterology, University Hospital Leipzig

Heiner Wedemeyer, Germany Hannover Medical School

Stefan Zeuzem, GermanyKlinikum der J.W. Goethe-Universitat, Med. Klinik 1

Fabien Zoulim, FranceINSERM U1052, Lyon University, Hepatology Department, Hospices Civils de Lyon

01-26-C-HEP-part 1.indd 13 4/10/12 15:08:52

01-26-C-HEP-part 1.indd 14 4/10/12 15:09:00


[ 15 ]

CME ACCREDITATION

The 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep) is accredited by the European accreditation Council for Continuing medical Education (EaCCmE) to provide the following CmE activity for medical specialists. The EaCCmE is an institution of the European Union of medical Specialists (UEmS), www.uems.net.

The 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep) is designated for a maximum of (or ‘for up to’) 11 hours of European external CmE credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of medical Specialists and the american medical association, physicians may convert EaCCmE credits to an equivalent number of ama PRa Category 1 Credits™. information on the process to convert EaCCmE credit to ama credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEmS-EaCCmE for ECmEC credits are deemed to be accredited Group Learning activities (Section 1) as defined by the maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

01-26-C-HEP-part 1.indd 15 4/10/12 15:09:04


[ 16 ]

SPONSORS

PLATINuM

GOLD

SILVER

SPONSORS

The C-Hep Congress gratefully acknowledges the generous support of the Sponosrs

01-26-C-HEP-part 1.indd 16 4/10/12 15:09:05


[ 17 ]

ACkNOwLEDGEMENTS

PLATINuM

Janssen Pharmaceutical Companies of Johnson & Johnson50-100 Holmers Farm Way, High Wycombe, HP12 4DP United KingdomContact: Sarah WalkerTel: +44 7876.217.895 Fax: +44 131.301.0054 Email: [email protected] Website: www.stop-hepatitis-c.info

Janssen Pharmaceutical Companies of Johnson & JohnsonJanssen is committed to improving the lives of people impacted by hepatitis C worldwide by establishing innovative treatment regimens that significantly improve patient outcomes. Our strong heritage in virology will help us to become a leader in hepatitis C through the development of products that redefine the standard of care. in 2011, we launched iNCiVO® (telaprevir), a protease inhibitor co-developed with Vertex Pharmaceuticals inc, for patients suffering from genotype 1 chronic HCV. Visit: www.stop-hepatitis-c.info

Today’s mSD is a global healthcare leader working to help the world be well. mSD is known as merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information visit www.merck.com and connect with us on Twitter, Facebook and youTube.

Merck Sharp & Dohme (MSD)One merck DrivePO Box 100Whitehouse Station, New Jersey 08889

01-26-C-HEP-part 1.indd 17 4/10/12 15:09:07


[ 18 ]

ACkNOwLEDGEMENTS

F. Hoffmann-La Roche LtdF. Hoffmann-La Roche aG, Pharmaceuticals Division, Bldg 74/3O.Z02.18, CH-4070 Basel, SwitzerlandContact: Gabriel SchnetzlerTel: +41 (0) 61.687.76.76Fax: +41 (0) 61.688.23.48Email: [email protected]: www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare, with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.in the treatment of hepatitis C, Roche’s PEGaSyS (peginterferon alfa-2a [40KD]) has proven efficacy supported by extensive clinical and real-world experience. Over the last decade PEGaSyS has been studied in 11 pivotal clinical trials involving over 5700 patients, and more than 2 million patients have now been treated globally.

GOLD

Gilead Sciences Ltd 2 Roundwood avenue, Stockley Park Uxbridge UB11 1aF United Kingdom

Gilead Sciences, a research-based biopharmaceutical company, discovers, develops and commercializes innovative medicines in areas of unmet need. Gilead’s focus includes liver disease, HiV/aiDS and serious cardiovascular and respiratory conditions. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases. Founded in 1987 in Foster City, California, Gilead employs some 4,000 people worldwide. as Gilead grows, so do our responsibilities as a corporate citizen and since 2003 our HiV access program has provided antivirals at substantially reduced prices in low- and middle-income countries.

boehringer Ingelheim Binger Strasse 173 ingelheim, 55216Germany Contact: Dr Reinhard malinTel: (0) 6132.77.90815Fax: (0) 6132.77.6601Email: [email protected]: www.boehringer-ingelheim.com

Boehringer ingelheim is a research-driven pharmaceutical group of companies dedicated to serving humankind by researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. Virology is one of seven R&D areas with Hepatitis C at the centre of interest. Our dedicated HCV treatment development programme, HCVersoTm, aims to deliver improved HCV treatment outcomes for patients, breaking down the barriers of current regimens and pursue new interferon free treatment paradigm.as part of this program, Boehringer ingelheim has advanced the clinical investigation of the 2nd wave protease inhibitor faldaprevir, and the combination of faldaprevir with the polymerase inhibitor Bi 207127 in an interferon-free setting into Phase iii.

01-26-C-HEP-part 1.indd 18 4/10/12 15:09:08


[ 19 ]

ACkNOwLEDGEMENTS

Abbott200 abbott Park Road06mi, aP34-3abbott Park 60064-6189Contact: Dirk van Eeden, director Public affairs, abbott internationalTel & Fax: +1 847.938.8848 Email: [email protected] Website: www.abbott.com

bristol-Myers Squibb GmbH & Co. KGaAContact: mr. Knut Hannibal-TeichmannTel: +49 89.12142.474Fax: +49 89.12142.464Email: [email protected]

abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

Bristol-myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis b, HiV, psychiatric disorders, and rheumatoid arthritis. For more information, please visit www.bms.com.

SILVER

01-26-C-HEP-part 1.indd 19 4/10/12 15:09:09


[ 20 ]

ACkNOwLEDGEMENTS

SPONSORS

Rottapharm | Madaus Colonia-allee 15 Koln, 51067 Germany Contact: Cristina LambertiTel: +39 (0) 39.73.901Fax: +39 (0) 39.73.90.372Email: [email protected]: www.rotta.com

The italian company Rottapharm|madaus has a significant worldwide franchise and expertise in several medical fields, including hepatology/gastroenterology, with leading products such as Legalon and Legalon-SiL (silymarin and silibinin, sold in most Countries as anti-toxic treatments for liver pathologies ranging from NaSH to acute mushroom poisoning).New R&D developments in the same area will further strengthen the company’s relationship with Hepatologists over the next few years. in particular, Silibinin has been granted the orphan drug designation from Ema and FDa for the prevention of recurrent hepatitis C in liver transplant recipients.

Idenix Pharmaceuticals, Inc.60 Hampshire StreetCambridge, ma 02139Contact: Kelly BarryTel: 617.995.9800Fax: 617.995.9801Email: [email protected] Website: www.idenix.com

Novartis Pharma AGForum 1, Novartis Campus, 4056 BaselContact: Christian C. RothTel: +41 (0) 61.324.3122Email: [email protected]: www.novartis.com

idenix Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Our current primary research and development focus is on the treatment of patients infected with the hepatitis C virus (HCV). We are headquartered in Cambridge, massachusetts. Our clinical development operations and drug discovery operations are conducted in Cambridge and the company’s European laboratory in montpellier, France.The chemists and biologists leading the idenix drug discovery team have substantial experience in the creation or modification of antiviral drugs. idenix is able to rapidly discover compounds amenable to robust development and manufacturing processes. Building on our expertise in nucleoside chemistry and other small molecule chemistry and biology, we believe idenix is well positioned to become a leader in antiviral pharmaceuticals.

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. in 2011, the Group achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 126,000 full-time-equivalent associates and operate in more than 140 countries around the world.

01-26-C-HEP-part 1.indd 20 4/10/12 15:09:11


[ 21 ]

EXhIBITION FOORPLAN

MAINENTRANCE

POSTERS

REGISTRATION

EXHIbITION

2

63

HALL

A

HALL

b

COMPANY STAND

Bristol-myers Squibb 3

merck Sharp & Dohme (mSD) 2

Rottapharm | madaus 6

01-26-C-HEP-part 1.indd 21 4/10/12 15:09:16


[ 22 ]

PARTNERS

EVENT PARTNERS

MEDIA PARTNERS

The american Conference for the Treatment of HiV (aCTHiV) may 10-12, 2012Denver, CO, USa

E-aHPBa congress December 12-13, 2012

UK, London

6th Conference of the Union Europe Region July 4-6, 2012

UK, London

Prague Hepatology meeting 2012 September 20-22, 2012Prague, Czech Republic

international Liver Cancer association (iLCa)September 14-16, 2012

Berlin, Germany

01-26-C-HEP-part 1.indd 22 4/10/12 15:09:19


[ 23 ]

ENDORSEMENTS

01-26-C-HEP-part 1.indd 23 4/10/12 15:09:20


[ 24 ]

GENERAL INFORMATION

CONGRESS VENUELeonardo Royal Hotel BerlinOtto-Braun-Strasse 90D-10249, Berlin, GermanyTel.: +49 (0) 30-755 430 0Fax: +49 (0) 30-755 430 810Email: [email protected]: www.leonardo-hotels.com/Royal_Berlin_Hotel

LANGUAGEEnglish is the official language of the Congress.

REGISTRATION AND hOSPITALITY DESkThe Registration Desk will operate during the following hours:

Thursday, October 18, 2012 11:00-20:00

Friday, October 19, 2012 08:00-17:30

Saturday, October 20, 2012 08:00-12:40

CONGRESS kIT AND NAME TAGName tags are included in your personal Congress Kit. Please wear your name tag during all sessions and social events.

Key colors for name tags:

CERTIFICATE OF ATTENDANCEyour Certificate of attendance is included in your personal Congress Kit.

C-hEP FEEDBACk FORMPlease note that you have a C-Hep-CmE Feedback Form in your Congress Kit. We would greatly appreciate hearing your comments. Once completed, this form may be handed in to the Registration Desk.

LIST OF PARTICIPANTSa list of pre-registered participants is displayed on the notice board. Please correct or add your name and address wherever necessary.

INTERNET AND EMAILFree internet and email facilities will be available during Congress hours.

REFREShMENTSCoffee and tea will be served during the coffee breaks between sessions, as specified in the Timetable.

LUNChESa buffet lunch will be served for participants of the Congress on Friday, October 19, 2012 12:15-13:00. Please present your name tag at the entrance.

2ND WORLD CONGRESS ON


C-HEP


blue: Participants

2ND WORLD CONGRESS ON


C-HEP


Orange: Faculty

01-26-C-HEP-part 1.indd 24 4/10/12 15:09:23


[ 25 ]

GENERAL INFORMATION

SPEAkERS’ PREVIEw ROOMSpeakers are invited to visit the Speakers’ Preview Room prior to their lecture and upload their presentation(s). Speakers should bring their slide presentations to be uploaded for their sessions no later than one break prior to the session in which they are scheduled. The Speakers’ Preview Room will be open during Congress hours as follows:


Friday, October 19, 2012 08:00-17:30


POSTER PRESENTATIONPoster presenters should plan to be beside their posters during the designated coffee breaks, as specified in the program. Please see the Congress Secretariat for board allocation at the Congress. Posters should be mounted on Thursday, October 18, 2012 at 14:00-17:30 and removed by 12:45 on Saturday, October 20, 2012.The Organizing Committee is not responsible for posters that are not removed on time.Poster presentation times are as follows:


Friday, October 19, 2012 09:00-17:30


EXhIBITION hOURSThursday, October 18, 2012 14:00-20:30

Friday, October 19, 2012 10:30-17:30


SAFETY AND SECURITYPlease do not leave your personal belongings, bags or suitcases unattended at anytime.

LIABILITYThe Congress Secretariat and Organizers cannot accept liability for personal accidents, nor loss of or damage to private property of participants, either during or directly arising from the 2nd World Congress on Controversies in the management of Viral Hepatitis (C-Hep). Participants should make their own arrange-ments with respect to health and travel insurance.

CONGRESS SECRETARIAT

01-26-C-HEP-part 1.indd 25 4/10/12 15:09:25

One liver. One life. One VIREAD.

First-line treatment for chronic hepatitis B (CHB) in adults with compensated liver disease and decompensated liver disease1

Reference: 1. VIREAD, Summary of Product Characteristics. January 2012.VIR/IHQ/12-09//1199 Date of preparation: September 2012

Viread® 245 mg film-coated tabletsActive substance: tenofovir disoproxil (as fumarate). Composition: Each Viread film-coated tablet contains 245 mg of tenofovir disoproxil (as fumarate). Excipients: core: croscarmellose sodium, lactose monohydrate, magnesium stearate (E572), microcrystalline cellulose (E460), pregelatinised starch (gluten free). Coating: glycerol triacetate (E1518), hypromellose (E464), indigo carmine aluminium lake (E132). lactose monohydrate, titanium dioxide (E171). Therapeutic indications: HIV-1 infection: in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults. Hepatitis B infection: for the treatment of chronic hepatitis B in adults with compensated liver disease (with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels

and histological evidence of active inflammation and/or fibrosis) or with decompensated liver disease. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Warning: contains lactose monohydrate. Undesirable effects: Very common (≥1/10): hypophosphatemia, dizziness, diarrhoea, vomiting, nausea, rash, asthenia. Common (≥1/100, <1/10): headache, abdominal pain, abdominal distension, flatulence, increased transaminases, fatigue. Uncommon (≥1/1,000, <1/100): hypokalemia, pancreatitis, rhabdomyolysis, muscular weakness, increased creatinine. Rare (≥1/10,000, <1/1,000): lactic acidosis, hepatic steatosis, hepatitis, angioedema, osteomalacia, myopathy, acute renal failure, renal failure, acute tubular necrosis, proximal

renal tubulopathy (including Fanconi syndrome), nephritis (including acute interstitial nephritis), nephrogenic diabetes insipidus. Other possible side effects: hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, hyperlactataemia, lipodystrophy, immune reactivation syndrome, osteonecrosis, hepatomegaly. Pharmaceutical form and pack sizes: Packs containing 30 and 3 x 30 film-coated tablets. Medicinal product subject to medical prescription. Information as of: January 2012. Marketing authorisation holder: GILEAD Sciences International Ltd., Cambridge, CB21 6GT, UK. Representative in Germany: Gilead Sciences GmbH, 82152 Martinsried b. Munich.

Maximising outcomes

GIVI0041_Hep-C-Advert_AW.indd 1 18/09/2012 11:5301-26-C-HEP-part 1.indd 26 4/10/12 15:09:28



C-HEP


SCIENTIFIC PROGRAM


27-34-C-HEP-part 2.indd 1 4/10/12 14:58:21


[ 28 ]

NOTES

27-34-C-HEP-part 2.indd 2 4/10/12 14:58:22


[ 29 ]

14:00-16:00 PLENARY SESSION 1 HEPATITIS C – ADDRESSING THE CHALLENGE moderators: Jürgen Rockstroh, Germany; Jonathan M. Schapiro, Israel

14:00-14:05 Chairpersons Conference Welcome address

14:05-14:30 HCV in 2020: any cases left? Rafael Esteban, Spain14:30-14:35 Discussion

14:35-15:00 HCV vaccine: where do we stand? Ulrich Spengler, Germany15:00-15:05 Discussion

interferon-free HCV therapy: are we getting there?15:05-15:25 No: Graham Foster, UK15:25-15:45 yes: Heiner Wedemeyer, Germany15:45-16:00 Discussion

16:00-17:30 PIPELINE ShOwCASE NEW DRUGS ON THE HORIzON moderator: Jonathan M. Schapiro, Israel

16:00-16:05 introduction

16:05-16:20 Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer, Germany Presentation supported by BMS

16:20-16:35 Combination Daa Therapy for Hepatitis C Douglas Mayers, USA Presentation supported by Idenix

16:35-16:50 Host targeting therapies for the treatment of Hepatitis C Claudio Avila, Switzerland Presentation supported by Novartis

16:50-17:05 The aNNaPURNa study: Evaluating the Combination of Setrobuvir, Danoprevir/r and Ribavirin With or Without mericitabine in Patients With Chronic Hepatitis C Eckart Schott, Germany Presentation Supported by Roche

17:05-17:20 Silibinin dihydrogensuccinate for the prevention of hepatitis C recurrence after liver transplantation and treatment of non-responders to anti-HCV therapy Lucio Rovati, Italy Presentation Supported by Rottapharm | Madaus

17:20-17:30 Panel Discussion

17:30-18:00 Coffee Break and Poster Exhibition

SCIENTIFIC PROGRAM

[ HALL A ]

THURSDAy, OCTObER 18, 2012

27-34-C-HEP-part 2.indd 3 4/10/12 14:58:23


[ 30 ]

18:00-19:15 SATELLITE SYMPOSIuM JANSSEN PhARMACEuTICALS DAAs: RISING STANDARDS IN PATIENT CARE

18:00-18:05 Welcome and introduction: Thomas berg, Germany18:05-18:25 Practical recommendations in the era of Daas: Vlad Ratziu, France18:25-18:45 managing Daa treatment in HiV-HCV co-infected patients: Massimo Puoti, Italy18:45-19:05 Understanding our patients: challenging clinical cases: Marina berenguer, Spain19:05-19:15 Summary and key learnings: Thomas berg, Germany

19:15-20:30 wELCOME RECEPTION Sponsored by Abbott

SCIENTIFIC PROGRAM

[ HALL A ]

THURSDAy, OCTObER 18, 2012

27-34-C-HEP-part 2.indd 4 4/10/12 14:58:24


[ 31 ]

09:00-11:00 PLENARY SESSION 2 HCV DIRECT ACTING ANTIVIRALS: HOW HAVE THE TREATMENT PARADIGMS CHANGED moderators: Stefan zeuzem, Germany; Eckart Schott, Germany

09:00-09:05 Overview of HCV sessions by HCV Program Director: Stefan zeuzem, Germany

Direct antivirals: how have the treatment paradigms changed?09:05-09:10 moderators introduction

HCV Direct acting antivirals:09:10-09:30 in treatment naïve: Stanislas Pol, France09:30-09:50 in treatment experienced: Thomas berg, Germany09:50-10:10 Toxicity management: Christoph Hezode, France10:10-10:40 Drug-drug interactions: David back, UK10:40-11:00 Panel discussion


11:30-12:15 SESSION 3 (parallel session) DO WE NEED TO kNOW GENETIC FACTORS SUCH AS IL28b FOR TREATMENT DECISION MAkING?

11:30-11:45 yes: Vincent Soriano, Spain11:45-12:00 No: Mathew Albert, France12:00-12:15 Discussion

11:30-12:15 SESSION 4 (parallel session) HCV THERAPy IS FOR SPECIALISTS ONLy?

11:30-11:45 yes: Marion Peters, USA11:45-12:00 No: Michael biermer, Germany12:00-12:15 Discussion

12:15-13:00 Lunch

SCIENTIFIC PROGRAM

[ HALL A ]

[ HALL b ]

FRIDAy, OCTObER 19, 2012

27-34-C-HEP-part 2.indd 5 4/10/12 14:58:26


[ 32 ]

[ HALL b ]

13:00-14:15 SATELLITE SYMPOSIuM MERCK ShARP & DOhME SUCCESSFUL HCV TREATMENT IN THE REAL WORLD: LESSONS FROM CLINICAL PRACTICE Chairperson: Jürgen Rockstroh, Germany

13:00-13:05 Welcome and Opening Remarks: Jürgen Rockstroh, Germany13:05-13:20 Emerging Evidence Guiding Clinical Practice: Christoph Sarrazin, Germany13:20-13:40 Optimizing Outcomes with Protease inhibitors: adverse Events management and Prevention of Resistance: Jean Michel Pawlotsky, France13:40-14:00 Protease inhibitors in Practice: Case Studies: Geoffrey Dusheiko, UK14:00-14:10 Panel Discussion14:10-14:15 Closing Remarks: Jürgen Rockstroh, Germany

14:15-15:45 PLENARY SESSION 5 HEPATITIS: STATE OF THE ART CLINICAL CARE

14:15-14:35 Fatty liver disease: what do we know? Claus Niederau, Germany14:35-14:55 Vitamin D and liver disease: Which role does it play? Christian M. Lange, Germany14:55-15:15 End-stage liver disease: What is new? Marion Peters, USA15:15-15:35 Treatment of HCC: state of the art: Massimo Puoti, Italy17:35-17:45 Panel Discussion

15:45-16:15 Coffee Break and Poster Prize Ceremony

16:15-17:00 SESSION 6 (parallel session) SHOULD PATIENTS WAIT FOR DAA COMbINATION THERAPy?

16:15-16:30 yes: Patrick Ingiliz, Germany 16:30-16:45 No: Geoffrey Dusheiko, UK16:45-17:00 Discussion

16:15-17:00 SESSION 7 (parallel session) RESISTANCE TO HCV PROTEASE INHIbITORS: GAME OVER?

16:15-16:30 yes: Jean Michel Pawlotsky, France16:30-16:45 No: Christoph Sarrazin, Germany16:45-17:00 Discussion

SCIENTIFIC PROGRAM

[ HALL A ]


27-34-C-HEP-part 2.indd 6 4/10/12 14:58:27


[ 33 ]

17:00-17:30 SESSION 8 (parallel session) HOW TO TREAT HCV RELAPSE AFTER LIVER TRANSPLANT? iNTERaCTiVE CaSE SESSiON

Case discussion: How to treat HCV relapse after OLTX Raffaele bruno, Italy

17:00-17:30 SESSION 9 (parallel session) HOW TO TREAT HCV IN HIV CO-INFECTION iNTERaCTiVE CaSE SESSiON Supported by an unrestricted grant from Boehringer Ingelheim

Case discussion: How to treat HCV in HiV coinfection Stefan Mauss, Germany

SCIENTIFIC PROGRAM

[ HALL A ]

[ HALL b ]


27-34-C-HEP-part 2.indd 7 4/10/12 14:58:28


[ 34 ]

08:30-10:30 PLENARY SESSION 10 HbV THERAPy IN 2012 moderators: Fabien zoulim, France; Jörg Petersen, Germany

08:30-08:35 Overview of HBV sessions by HBV Program Director: Fabien zoulim, France

08:35-09:00 Hepatitis B Therapy: State of the art and open challenges: Jörg Petersen, Germany

is there a need for combination therapy? 09:00-09:15 yes: Florian van bömmel, Germany09:15-09:30 No: Maria buti, Spain

09:30-09:50 HBV preventive and therapeutic vaccines: what is new? Marie-Louise Michel, France

09:50-10:10 Hepatitis Delta: What is new? Heiner Wedemeyer, Germany

10:10-10:30 Panel discussion


11:00-11:45 PLENARY SESSION 11 THE CHALLENGING HEPATITIS b CASE iNTERaCTiVE CaSE SESSiON aND DiSCUSSiON moderator: Fabien zoulim, France Supported by an unrestricted grant from Gilead Sciences Europe Ltd.

Case discussion: The challenging hepatitis B case Mark Nelson, UK karine Lacombe, France

11:45-12:45 PLENARY SESSION 12 HCV – LOOkING TO THE FUTURE

11:45-12:05 Strategies to prevent HCC: what can we do? Mark Thursz, UK

12:05-12:20 Can we afford HCV Daas for all? Maud Lemoine, France

12:20-12:45 What are the remaining challenges in hepatitis research? Michael Manns, Germany

12:45-13:00 FAREwELL TOAST

SCIENTIFIC PROGRAM

[ HALL A ]

SATURDAy, OCTObER 20, 2012

27-34-C-HEP-part 2.indd 8 4/10/12 14:58:29



C-HEP


INDEX


The academy for Clinical Debates & Controversies in medicine announces

35-36-C-HEP-index.indd 1 4/10/12 15:01:52

1

Name Program Page

A

Albert, Matthew 31

Avila, Claudio 29

B

Back, David 31

Berenguer, Marina 30

Berg, Thomas 30, 31

Biermer, Michael 31

Bruno, Raffaele 33

Buti, Maria 34

D

Dusheiko, Geoffrey 32

E

Esteban, Rafael 29

F

Foster, Graham 29

H

Hezode, Christoph 31

I

Ingiliz, Patrick 32

L

Lacombe, Karine 34

Lange, Christian M. 32

Lemoine, Maud 34

Name Program Page

M

Manns, Michael P. 34

Mauss, Stefan 33

Mayers, Douglas 29

Michel, Marie-Louise 34

N

Nelson, Mark 34

Niederau, Claus 32

P

Pawlotsky, Jean Michael 32

Peters, Marion 31, 32

Petersen, Jörg 34

Pol, Stanislas 31

Puoti, Massimo 30, 31, 32

R

Ratziu, Vlad 30

Rockstroh, Jürgen 29, 32

Rovati, Lucio 29

S

Sarrazin, Christoph 32

Schapiro, Jonathan M. 29

Schott, Eckart 29, 31

Soriano, Vicente 31

Spengler, Ulrich 29

T

Thursz, Mark R. 34

2

Name Program Page

V

van Bömmel, Florian 34

W

Wedemeyer, Heiner 29, 34

Z

Zeuzem, Stefan 31

Zoulim, Fabien 34








THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITISBERLIN, GERMANY • OCTOBER 18-20, 2012

C-HEP PARTICIPANTS CAME FROM…

37 Countries (as of October 2, 2012)

Azerbaijan Bahrain Belgium Canada Czech Republic

Denmark Estonia Finland France Georgia

Germany Greece Hungary India Israel

Italy Japan Lithuania Luxembourg Malta

Nigeria Norway Poland Portugal Qatar

Romania Russia Serbia Slovak Republic Spain

Sweden Switzerland Thailand Turkey UK

USA Vietnam


THE 3RD WORLD CONGRESS ON


C-HEP

ISTANBUL, 2013See you there!



C-HEP


PROGRAM



c-hep final book

Documents

plenary session

chep participants

world congress oncontroversies

interactive case session

hall a14

hall a08

hall b09

hcv therapy